WILMINGTON, Del., June 5, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced the transmission of its Abbreviated New Drug ...
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, is advancing a two-pronged approach to bring ...
(RTTNews) - NRx Pharmaceuticals, Inc. (NRXP), Thursday said it has submitted Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for preservative-free IV ketamine ...
Granting of Suitability Petition enables re-filing of Abbreviated New Drug Application (ANDA) for NRx’s patent-pending preservative-free ketamine product NEW YORK, NY / ACCESS Newswire / September 24, ...
The company has refiled its Abbreviated New Drug Application (“ANDA”) for KETAFREE (TM), a preservative-free IV ketamine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback